Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2004 October;52(5) > Minerva Cardioangiologica 2004 October;52(5):433-46

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS  INTERVENTIONAL CARDIOLOGY 

Minerva Cardioangiologica 2004 October;52(5):433-46

Copyright © 2004 EDIZIONI MINERVA MEDICA

language: English

New and viable cells to replace lost and malfunctioning myocardial tissue

Hassink R. J., Passier R., Goumans M. J., Mummery C. L., Doevendans P. A.


PDF


The use of stem cells for cardiac repair is a promising opportunity for developing new treatment strategies as the applications are theoretically unlimited and lead to actual cardiac tissue regeneration. Human embryonic stem cells were only recently cloned and their capacity to differentiate into true cardiomyocytes makes them in principle an unlimited source of transplantable cells for cardiac repair, although practical and ethical constraints exist. Also, the study of embryonic stem cells and their differentiation into cardiomyocytes will bring forth new insights into the molecular processes involved in cardiomyocyte-development and -proliferation, which could lead to the development of other strategies to augment in vivo cardiomyocyte numbers. On the other hand, somatic stem cells are alternative cell sources that can be used for cell transplantation purposes. They do not evoke ethical issues and bear less ethical constraints. However, they also appear to be much more restricted in their differentiation potential than the embryonic stem cells. Here we discuss the use of both cell types, embryonic and somatic stem cells, in relation with their importance for the clarification of cardiomyocyte-development and their possible usefulness for clinical therapy.

top of page